Top-Rated StocksTop-RatedNASDAQ:DNLI Denali Therapeutics (DNLI) Stock Forecast, Price & News $31.27 +0.20 (+0.64%) (As of 10:02 AM ET) Add Compare Share Share Today's Range$30.86▼$31.3650-Day Range$23.04▼$32.0252-Week Range$20.76▼$39.43Volume15,003 shsAverage Volume700,937 shsMarket Capitalization$4.28 billionP/E RatioN/ADividend YieldN/APrice Target$52.09 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Denali Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside67.7% Upside$52.09 Price TargetShort InterestBearish8.08% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment0.54Based on 9 Articles This WeekInsider TradingSelling Shares$418,754 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.31) to ($3.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector433rd out of 986 stocksBiological Products, Except Diagnostic Industry72nd out of 163 stocks 3.5 Analyst's Opinion Consensus RatingDenali Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.09, Denali Therapeutics has a forecasted upside of 67.7% from its current price of $31.07.Amount of Analyst CoverageDenali Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.08% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDenali Therapeutics has received a 74.49% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Denali Therapeutics is -0.84. Previous Next 3.1 News and Social Media Coverage News SentimentDenali Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Denali Therapeutics this week, compared to 3 articles on an average week.Search Interest8 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows10 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $418,754.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions67.26% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($3.31) to ($3.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -10.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -10.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Denali Therapeutics (NASDAQ:DNLI) StockDenali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.Read More Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Stock News HeadlinesMay 18, 2023 | marketbeat.comAnalysts Say These 2 Mid-Cap Biotechs Have 2x PotentialThese two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.June 7, 2023 | finance.yahoo.comWhy Is Denali Therapeutics Inc. (DNLI) Up 11.9% Since Last Earnings Report?June 9, 2023 | Edge On The Street (Ad)All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A SupercycleMore automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...June 6, 2023 | msn.comOppenheimer Maintains Denali Therapeutics (DNLI) Outperform RecommendationJune 6, 2023 | msn.comBiogen (BIIB) to End One of Two Parkinson's Studies on BIIB122June 5, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Denali Therapeutics (DNLI)June 5, 2023 | msn.comBiogen, Denali to halt late-stage trial for Parkinson’s disease drugJune 5, 2023 | markets.businessinsider.comBerenberg Bank Sticks to Its Buy Rating for Denali Therapeutics (DNLI)June 9, 2023 | Edge On The Street (Ad)All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A SupercycleMore automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...June 1, 2023 | americanbankingnews.comZacks Research Research Analysts Lift Earnings Estimates for Denali Therapeutics Inc. (NASDAQ:DNLI)May 31, 2023 | finance.yahoo.comDenali Therapeutics (NASDAQ:DNLI) Is In A Good Position To Deliver On Growth PlansMay 30, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Hold on Denali Therapeutics (DNLI)May 26, 2023 | americanbankingnews.comBrokerages Set Denali Therapeutics Inc. (NASDAQ:DNLI) Price Target at $54.58May 20, 2023 | americanbankingnews.comInsider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Sells 10,000 Shares of StockMay 18, 2023 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Trading Down 6.2%May 16, 2023 | americanbankingnews.comCantor Fitzgerald Brokers Lower Earnings Estimates for Denali Therapeutics Inc. (NASDAQ:DNLI)May 15, 2023 | finance.yahoo.comWhy Shares of Denali Therapeutics Are Up MondayMay 13, 2023 | americanbankingnews.comDenali Therapeutics Inc. Forecasted to Post Q2 2023 Earnings of ($0.83) Per Share (NASDAQ:DNLI)May 13, 2023 | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) to Post Q2 2023 Earnings of ($0.78) Per Share, HC Wainwright ForecastsMay 12, 2023 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Price Target Cut to $30.00May 11, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)May 11, 2023 | markets.businessinsider.comBerenberg Bank Remains a Buy on Denali Therapeutics (DNLI)May 9, 2023 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)May 9, 2023 | finance.yahoo.comDenali (DNLI) Q1 Earnings Miss Estimates, Pipeline in FocusMay 9, 2023 | finanznachrichten.deDenali Therapeutics Inc.: Denali Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsMay 9, 2023 | msn.comWedbush Maintains Denali Therapeutics (DNLI) Outperform RecommendationMay 9, 2023 | msn.comHC Wainwright & Co. Reiterates Denali Therapeutics (DNLI) Buy RecommendationSee More Headlines DNLI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNLI Company Calendar Last Earnings5/08/2023Today6/09/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DNLI CUSIPN/A CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees380Year Founded2015Price Target and Rating Average Stock Price Forecast$52.09 High Stock Price Forecast$105.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+67.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-325,990,000.00 Net Margins-365.21% Pretax Margin-365.19% Return on Equity-40.01% Return on Assets-27.50% Debt Debt-to-Equity RatioN/A Current Ratio3.39 Quick Ratio3.39 Sales & Book Value Annual Sales$108.46 million Price / Sales39.21 Cash FlowN/A Price / Cash FlowN/A Book Value$7.68 per share Price / Book4.05Miscellaneous Outstanding Shares136,890,000Free Float126,075,000Market Cap$4.25 billion OptionableOptionable Beta1.33 Social Links Key ExecutivesRyan J. WattsPresident, Chief Executive Officer & DirectorAlexander O. SchuthSecretary, Chief Operating & Financial OfficerCarole HoChief Medical Officer & Head-DevelopmentDana AndersenCTO & Chief Manufacturing OfficerJoe LewcockChief Scientific OfficerKey CompetitorsAbcamNASDAQ:ABCMHalozyme TherapeuticsNASDAQ:HALOGinkgo BioworksNYSE:DNAVaxcyteNASDAQ:PCVXVir BiotechnologyNASDAQ:VIRView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 3,996 shares on 6/1/2023Ownership: 0.008%ProShare Advisors LLCSold 4,622 shares on 5/26/2023Ownership: 0.016%JPMorgan Chase & Co.Sold 37,989 shares on 5/18/2023Ownership: 0.107%New York State Common Retirement FundSold 16,060 shares on 5/18/2023Ownership: 0.099%International Biotechnology Trust PLCBought 48,575 shares on 5/18/2023Ownership: 0.063%View All Insider TransactionsView All Institutional Transactions DNLI Stock - Frequently Asked Questions Should I buy or sell Denali Therapeutics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DNLI shares. View DNLI analyst ratings or view top-rated stocks. What is Denali Therapeutics' stock price forecast for 2023? 12 equities research analysts have issued twelve-month target prices for Denali Therapeutics' shares. Their DNLI share price forecasts range from $30.00 to $105.00. On average, they anticipate the company's stock price to reach $52.09 in the next year. This suggests a possible upside of 67.7% from the stock's current price. View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts. How have DNLI shares performed in 2023? Denali Therapeutics' stock was trading at $27.81 at the beginning of the year. Since then, DNLI stock has increased by 11.7% and is now trading at $31.07. View the best growth stocks for 2023 here. When is Denali Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our DNLI earnings forecast. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) issued its earnings results on Monday, May, 8th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.10. The firm had revenue of $35.14 million for the quarter, compared to analyst estimates of $29.88 million. Denali Therapeutics had a negative net margin of 365.21% and a negative trailing twelve-month return on equity of 40.01%. The company's quarterly revenue was down 16.6% on a year-over-year basis. During the same period last year, the firm earned ($0.53) earnings per share. What ETFs hold Denali Therapeutics' stock? ETFs with the largest weight of Denali Therapeutics (NASDAQ:DNLI) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), iShares Biotechnology ETF (IBB), Global X Aging Population ETF (AGNG) and Invesco Nasdaq Biotechnology ETF (IBBQ). What is Ryan Watts' approval rating as Denali Therapeutics' CEO? 1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG). When did Denali Therapeutics IPO? (DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. What is Denali Therapeutics' stock symbol? Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI." Who are Denali Therapeutics' major shareholders? Denali Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.23%), BlackRock Inc. (6.93%), Temasek Holdings Private Ltd (5.04%), Wellington Management Group LLP (3.80%), State Street Corp (3.35%) and Price T Rowe Associates Inc. MD (2.58%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Denali Therapeutics' stock price today? One share of DNLI stock can currently be purchased for approximately $31.07. How much money does Denali Therapeutics make? Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $4.25 billion and generates $101.46 million in revenue each year. The company earns $-325,990,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis. How many employees does Denali Therapeutics have? The company employs 380 workers across the globe. How can I contact Denali Therapeutics? Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at hansen@dnli.com. This page (NASDAQ:DNLI) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.